Tango Therapeutics officer plans $454K share sale
Three earlier 10b5-1 sales were each 27,000 shares, dated August 3, September 1, and October 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tango Therapeutics, Inc. (TNGX) lists Officer Adam Crystal’s planned sale of 20,000 common shares, with an aggregate market value of $454,400, for November 2, 2026. The shares are to be received through stock-option exercises over the next three months; the notice states that acquisition and payment dates will be the exercise/sale dates. It also lists three prior sales by Adam Crystal, each of 27,000 shares, on August 3, September 1, and October 1, 2026.
Key Figures
Key Terms
Rule 144 regulatory
10b5-1 Sales regulatory
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Adam Crystal’s recent TNGX sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.